ADMA
Price
$16.61
Change
-$0.92 (-5.25%)
Updated
Feb 4, 02:19 PM (EDT)
Capitalization
4.17B
43 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$7.36
Change
-$0.32 (-4.17%)
Updated
Feb 4, 03:26 PM (EDT)
Capitalization
1.07B
15 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADMA vs VIR

Header iconADMA vs VIR Comparison
Open Charts ADMA vs VIRBanner chart's image
ADMA Biologics
Price$16.61
Change-$0.92 (-5.25%)
Volume$2.96K
Capitalization4.17B
Vir Biotechnology
Price$7.36
Change-$0.32 (-4.17%)
Volume$300
Capitalization1.07B
ADMA vs VIR Comparison Chart in %
View a ticker or compare two or three
VS
ADMA vs. VIR commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Buy and VIR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ADMA: $17.52 vs. VIR: $7.68)
Brand notoriety: ADMA and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 66% vs. VIR: 54%
Market capitalization -- ADMA: $4.17B vs. VIR: $1.07B
ADMA [@Biotechnology] is valued at $4.17B. VIR’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 1 FA rating(s) are green whileVIR’s FA Score has 1 green FA rating(s).

  • ADMA’s FA Score: 1 green, 4 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, both ADMA and VIR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 6 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).

  • ADMA’s TA Score: 6 bullish, 5 bearish.
  • VIR’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, VIR is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а +5.67% price change this week, while VIR (@Biotechnology) price change was -0.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.39%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +33.05%.

Reported Earning Dates

ADMA is expected to report earnings on Mar 19, 2026.

VIR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($4.17B) has a higher market cap than VIR($1.07B). VIR YTD gains are higher at: 27.363 vs. ADMA (-3.947). ADMA has higher annual earnings (EBITDA): 172M vs. VIR (-541.01M). VIR has more cash in the bank: 507M vs. ADMA (61.4M). ADMA has less debt than VIR: ADMA (83.1M) vs VIR (100M). ADMA has higher revenues than VIR: ADMA (489M) vs VIR (14M).
ADMAVIRADMA / VIR
Capitalization4.17B1.07B390%
EBITDA172M-541.01M-32%
Gain YTD-3.94727.363-14%
P/E Ratio20.37N/A-
Revenue489M14M3,493%
Total Cash61.4M507M12%
Total Debt83.1M100M83%
FUNDAMENTALS RATINGS
ADMA vs VIR: Fundamental Ratings
ADMA
VIR
OUTLOOK RATING
1..100
514
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
36100
SMR RATING
1..100
1797
PRICE GROWTH RATING
1..100
5439
P/E GROWTH RATING
1..100
9930
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VIR's Valuation (53) in the null industry is in the same range as ADMA (74) in the Biotechnology industry. This means that VIR’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for VIR (100) in the null industry. This means that ADMA’s stock grew somewhat faster than VIR’s over the last 12 months.

ADMA's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for VIR (97) in the null industry. This means that ADMA’s stock grew significantly faster than VIR’s over the last 12 months.

VIR's Price Growth Rating (39) in the null industry is in the same range as ADMA (54) in the Biotechnology industry. This means that VIR’s stock grew similarly to ADMA’s over the last 12 months.

VIR's P/E Growth Rating (30) in the null industry is significantly better than the same rating for ADMA (99) in the Biotechnology industry. This means that VIR’s stock grew significantly faster than ADMA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMAVIR
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 13 days ago
73%
Declines
ODDS (%)
Bearish Trend 8 days ago
76%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CPCLX15.860.04
+0.25%
Calamos Phineus Long/Short C
VWINX25.850.03
+0.12%
Vanguard Wellesley® Income Inv
FSCHX13.24N/A
N/A
Fidelity Select Chemicals
GVEQX151.19-0.64
-0.42%
Government Street Equity
FRSIX14.70-0.27
-1.80%
Franklin Small-Mid Cap Growth C

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with VIR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
+0.11%
VIR - ADMA
46%
Loosely correlated
-0.39%
IMTX - ADMA
40%
Loosely correlated
-0.40%
CPRX - ADMA
40%
Loosely correlated
+0.88%
RGNX - ADMA
40%
Loosely correlated
+0.74%
XENE - ADMA
39%
Loosely correlated
+1.62%
More

VIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VIR has been loosely correlated with RLAY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then RLAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIR
1D Price
Change %
VIR100%
-0.39%
RLAY - VIR
57%
Loosely correlated
+6.38%
CLDX - VIR
56%
Loosely correlated
+2.07%
NRIX - VIR
53%
Loosely correlated
-1.76%
CRBU - VIR
52%
Loosely correlated
+6.85%
SANA - VIR
51%
Loosely correlated
-3.92%
More